On Catatonia and Dementia: A Case Report

Similar documents
Dementia With A Twist

Chapter 12 1/29/2018. Schizophrenia and Schizophrenia Spectrum Disorders. Epidemiology. Comorbidity. Lifetime prevalence of schizophrenia is 1%

Rapid Relief of Catatonia in Mood Disorder by Lorazepam and Diazepam. Yu Chi Huang, Chin Chuen Lin, Yi Yung Hung, Tiao Lai Huang

Prevalence and symptomatology of catatonia in elderly patients referred to a consultation-liaison psychiatry service

diagnostic consistency in catatonic schizophrenia

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Index. Note: Page numbers of article titles are in boldface type.

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations

Delirium & Dementia. Nicholas J. Silvestri, MD

Catatonia in a Tertiary Care Center in Eastern Part of Nepal: A Descriptive Study

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Introduction

Parkinsonian Disorders with Dementia

Drugs that poison the elderly

Every 67seconds, someone will develop Alzheimer's.

ROS: all remaining ROS negative

VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)

Diagnosis and Treatment of Alzhiemer s Disease

Dementia and Delirium: A Neurologist s Approach to Altered Mental Status. Case 1 4/7/11. Which of the following evaluations is your next step?

Mental Health Disorders Civil Commitment UNC School of Government

Parkinson s Disease. Gillian Sare

Shriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences

Dementia and Delirium:

A Neurologist s Approach to Altered Mental Status

A Case Report and Literature Review. Supplementary Material

A Healthy Brain. An Injured Brain

La catatonia nei pazienti bipolari: caratteristiche cliniche e risposta alla TEC. Pierpaolo Medda e Giulio Perugi AUOP, DMCS, Pisa, Italy

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Delirium. Geriatric Giants Lecture Series Divisions of Geriatric Medicine and Care of the Elderly University of Alberta

Management of Behavioral Problems in Dementia

Just Clear Them The Approach to Medical Clearance

For more information about how to cite these materials visit

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT

DSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)

Mental Health Rotation Educational Goals & Objectives

Periodic and Rhythmic Patterns. Suzette M LaRoche, MD Mission Health Epilepsy Center Asheville, North Carolina

Epilepsy DOJ Lecture Masud Seyal, M.D., Ph.D. Department of Neurology University of California, Davis

Objectives. Amanda Diamond, MD

Periodic catatonia with long-term treatment: a case report

Form D1: Clinician Diagnosis

Evolution of a concept: Apraxia/higher level gait disorder. ataxia v. apraxia gait = limb apraxia. low, middle, high gait disturbance levels

Severe Selective Mutism in a Young Individual with Schizophrenia

Tianeptine Dependence: A Case Report

The place for treatments of associated neuropsychiatric and other symptoms

TRI-STATE WEBINAR SERIES Catatonia and ASD: Hidden in Plain Sight

Pharmacological Treatment of Aggression in the Elderly

Fact Sheet Alzheimer s disease

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

The Safety and Efficacy of Ondansetron in the Treatment of Obsessive Compulsive Disorder

Clinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries

Delirium. A Plan to Reduce Use of Restraints. David Wensel DO, FAAHPM Medical Director Midland Care

Managing Behavioral Issues

DEMENTIA Dementia is NOT a normal part of aging Symptoms of dementia can be caused by different diseases Some symptoms of dementia may include:

Negative Symptoms of Schizophrenia: Treatments

Case Report Paradoxical Reaction to Alprazolam in an Elderly Woman with a History of Anxiety, Mood Disorders, and Hypothyroidism

Dementia Diagnosis Guidelines Primary Care

Delirium in the Elderly

POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital

Delirium in the Elderly

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

The confused binge drinker

DEMENTIA AND MEDICATION

Managing Challenging Behaviors

Schizophrenia FAHAD ALOSAIMI

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia

Carol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia

Neuroleptic malignant syndrome (NMS) was first

Our Senior Clients Clinical Issues Treatment Implications Interventions

Psychotic Disorders. Schizophrenia. Age Distribution of Onset 2/24/2009. Schizophrenia. Hallmark trait is psychosis

Aging with Bipolar Disorder. Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health

Autoimmune encephalopathieslatest. Prof Belinda Lennox Department of Psychiatry, University of Oxford

Update in Geriatrics: Choosing Wisely Primum Non Nocere

HDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D.

Is The Routine CT Head Scan Justified for Psychiatric Patients? A Prospective Study

3 COMMON PSYCHIATRIC DISORDERS IN OLDER ADULTS: NEW INSIGHTS

Behavioral Aspects of Parkinson s Disease

DOCTOR/PHYSICIAN S CERTIFICATE OF MEDICAL EXAMINATION. In the Matter of the Guardianship of an Alleged Incapacitated Person

Management of the Acutely Agitated Long Term Care Patient

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline

Referenced EEG Offers a New Way to Prescribe the Right Medication

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

NATALIE D. WEDER, MD, SUNANDA MURALEE, MD, HEATH PENLAND, MD, and RAJESH R. TAMPI, MD, MS

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT

Managing Challenging Behaviors

Imaging of Alzheimer s Disease: State of the Art

National Audit of Dementia

Cognitive disorders. Dr S. Mashaphu Department of Psychiatry

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

The psychological disorders

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

Keep Calm and Carry On Management of the Agitated Patient in the ED 29TH ANNUAL UPDATE IN EMERGENCY MEDICINE FEBRUARY 21-24, 2016

Delirium. Delirium. Delirium Etiology and Pathophysiology. Fall 2018

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

Delirium. A Geriatric Syndrome. Jonathan McCaleb, MD, CMD, HMDC UNSOM, Assistant Professor of Medicine Geriatrics / Hospice & Palliative Medicine

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Transcription:

http://escholarship.umassmed.edu/neurol_bull On Catatonia and Dementia: A Case Report Jordan Eisenstock Department of Neurology University of Massachusetts Memorial Medical Center, Worcester, MA The many pitfalls in the accurate diagnosis of dementias are well documented. While definitive diagnosis remains the goal, the limits of clinicopathologic knowledge and current technology oftentimes preclude firm decisions on a specific diagnosis, treatment and plans. This is particularly pertinent in those cases where the lines between neurology and psychiatry become somewhat blurred. In this report, I present the case of a patient with probable catatonic depression masquerading initially as frontotemporal dementia. Included is a brief discussion outlining our current knowledge about catatonia: its pertinent signs and symptoms for accurate diagnosis, its possible pathophysiologic mechanisms, and its relationship to dementia. Case Report The patient is a 56 year old right-handed gentleman who worked for several years in a supervisory role with the city department of public works and presented to our inpatient psychiatry unit for one month of worsening depression. Neurovegetative symptoms included insomnia, poor appetite and difficulty concentrating. There was a potential precipitating event as the patient s mother had re- cently passed away about two months prior to admission. With the exception of one prior psychiatric admission about 20 years earlier, also for worsening depression in the context of a family issue, the patient had never consistently required psychiatric attention. About two years prior to this admission he had seen an outpatient psychiatrist for a couple of months secondary to anxiety and panic symptoms and was started on an SSRI and a benzodiazepine. At the time of admission his only medications were HCTZ/ Triamterene for hypertension and Lumigan drops for glaucoma. He had been off of all neuropsychiatric medications for at least one year. His family history was only notable for question of late-onset dementia in the patient s mother. The neurology service came to be involved with this patient after the admitting examination by the psychiatry resident noted subtle perseveration on testing of extraocular movements, brisk reflexes and difficulty changing set despite a MMSE of 30/30. An initial neurology consultation yielded a diagnosis of Cognitive Symptoms Due to Depression and Correspondence to Jordan Eisenstock: jordan.eisenstock@umassmemorial.org Keywords: catatonia, electroconvulsive therapy, lorazepam, frontotemporal dementia, glutamate, GABA 12

Figure 1: Left image dated April 2006. Right image dated September 2007. the brisk reflexes were explained by cervical pathology on MRI. The inpatient psychiatry team resumed the patient s SSRI and added an atypical antipsychotic to the regimen and after two weeks the patient was discharged to his home. After continued deterioration despite compliance with medications the patient returned to the psychiatric emergency room a couple of months later. Again he was admitted to the inpatient psychiatry unit and trials of new SSRI s and atypical antipsychotic produced little clinical response. Shortly after discharge from the psychiatry service he was seen in the outpatient neurology clinic for follow-up of the original consultation. By this time the patient demonstrated minimal verbal output, most responses being a rather stereotypic and hesitant I don t know to all variety of questions. His family noted significant balance problems and he had fallen several times at home. In addition to mild rigidity and a grasp reflex, the patient was also noted to have startle myoclonus on examination. Subsequently the patient was directly admitted to the inpatient neurology service for a rapidly progressive dementia workup. Of significance, the patient s MRI showed minimal nonspecific white matter changes but no atrophy (Figure 1) and the laboratory findings were not suggestive of any underlying neurologic etiology (summarized in Table 1). An EEG in both the awake and asleep states was also normal. Over the course of the next four months the patient continued to decline, his verbal output decreased and there were few spontaneous movements. The patient was no longer getting out of bed to toilet himself, and he would not voluntarily eat even if the food was delivered to him. Though there was no formal disagreement, the psychiatry service suspected a dementia diagnosis and the neurology service tended toward a psychiatric etiology. Eventually a trial of ECT was ordered but was unfortunately suspended early secondary to presumed increased confusion in the setting of a urinary tract infection. Soon thereafter the patient was sent for a second opinion at another large academic medical center and returned to our outpatient 13

Table 1: Laboratory Summary Basic Metabolic Panel: normal Complete Blood Count: normal Liver Function Tests: normal Fasting Lipid Profile: normal Amylase/Lipase: normal Porphyrins: normal TSH: normal B12: normal Folate: normal CSF: 0 WBC, 0 RBC CSF: protein, glucose normal CSF: oligoclonal bands absent CSF: 14-3-3 negative Drugs of Abuse Screen: negative Sedimentation Rate: 45 (High, >20) HbA1C: normal Serum Protein Electrophoresis: normal Anti-Ri/Ma/Ta/Yo/Hu: negative VDRL/RPR: non-reactive Lyme Serum & CSF: unremarkable EBV CSF: negative Parv B19: negative VCA-IgM/IgG: negative EBNA-IgG: negative Admark Tau/ABeta42: unremarkable clinic one month later with the opinion of likely frontotemporal dementia. A decision had been made at the other institution to defer further ECT treatments, and the family was advised to explore nursing home placement options. A PET scan at the other institution had apparently demonstrated frontotemporal hypometabolism, which along with the clinical evaluation had precipitated the above diagnosis. Approximately six months after the first psychiatric hospitalization the patient returned to the inpatient neurology service. On the second evening of admission the patient rather suddenly and unexpectedly shifted from his longstanding stuporous state to a verbally and physically aggressive appearance. Intramuscular lorazepam was prescribed and within minutes the patient not only calmed down but voluntarily proceeded to get out of bed and go to the restroom. Later that evening he seemed to enjoy his dinner and conversed with family for the first time in months. A standing dose of lorazepam was initiated, and a previously suggested diagnosis of a catatonic-like, rather than frontotemporal-like, state was supported. It is now two and a half years since the pa- tient s initial presentation on the psychiatric unit. His current medications include memantine, topiramate and citalopram. For a short period of time the patient also required olanzepine secondary to paranoid thoughts about leaving his home; but this medication, along with maintenance lorazepam, has been successfully discontinued over the past several months. Though he has been unable to return to his previous work, his sense of humor has returned, his abnormal gait has resolved and his performance on formal neuropsychological testing has improved. A repeat PET scan was obtained and was normal, likely indicating that his previous scan was secondary to severe refractory depression rather than frontotemporal dementia. Discussion This patient s case illustrates many of the important teaching points when considering a diagnosis of catatonia. Most experts agree that catatonia is severely under-diagnosed in the neuropsychiatric community. Theories exist to explain this phenomenon, such as lack of teaching about catatonia in medical school, lack of agreed-upon classifications and guidelines for recognizing catatonia, and a general lack of understanding of the patho- 14

Table 2: Phenomenology of Catatonia EXCITEMENT STUPOR Hyperkinesis Stereotypies [repetitive/ritualistic movements, postures or utterances] Mannerisms [gestures that become abnormal with exaggeration] Euphoria Irritability Rigidity Autonomic Changes Hypertension Hyperpyrexia Diaphoresis Tachycardia Tachypnea Mydriasis Motor Behaviors Catalepsy Rigidity Waxy Flexibility [maintained immobile posture] Posturing Psychological Pillow [continued elevation of head as if supported by a pillow] Grimacing Negativism Gegenhalten Mutism Ambitendency [tendency to act in opposite ways from expected] Automatic Behaviors Obedience [tendency to follow commands even if harmful to self] Echolalia Echopraxia physiology behind the catatonic state. Indeed, there is no consensus in the literature regarding the phenomenology of catatonia (Table 2). As a consequence of unclear guidelines, there becomes a relative disproportionate reliance on the art and experience of medical decision-making by an individual physician. Inexperienced physicians become reluctant and hesitate to make the diagnosis and treat the condition. Catatonia is oftentimes relegated to diagnosis by exclusion or simply completely avoided. Delaying the treatment of catatonia negatively impacts patient care, as it significantly reduces the likelihood of traditional (ECT, benzodiazepine) treatment response. 1 Thus, deferring treatment until tests return to rule out known dementias might be detrimental. In fact, catatonia and dementia are not mutually exclusive diagnoses. 2 The three cardinal catatonic features (little or no spontaneous movement, mutism, refusal to eat or drink) are hallmark features of advanced dementia. 3 Perhaps treating the catatonic component of a patient s dementing condition may ameliorate a reversible or modifying factor. 4 At least 50 neurologic conditions have been identified as direct causes of secondary catatonia symptomatology. 5 Missing a catatonia treatment opportunity might greatly alter a patient s level of functioning. Not surprisingly the theories about catatonia pathophysiology and known dementias overlap considerably. Theories include deficits in cortical development, dopaminergic hypoactivity, low GABA-A receptor binding, frontal anomalies, dysfunction of norepinephrine and serotonin transmission and of course glutamatergic dysfunction. 5,6 A recent article reviewed adjunctive glutamate antagonist therapies in the treatment of catatonia and noted possible response with medications such as amantadine, memantine and topiramate. 6 On the other hand, modalities that are now viewed with suspicion in the demented patient, such as benzodiazepines or even ECT, might be more welcomed with further study. The literature regarding the possibility of lorazepam-responsive dementias illustrates this trend. 7 As awareness of the catatonic state and its many varieties of presentation increases, so too might the 15

available multidimensional forms of treatment for both catatonia and dementia. References 1. Caroff SN, Ungvari GS, Bhati MT, Datto CJ, O Reardon JP. Catatonia and prediction of response to electroconvulsive therapy. Psychiatr Ann 2007;37:57-63. 2. Alisky JM. Is the immobility of advanced dementia a form of lorazepam-responsive catatonia? Am J of Alzheimers Dis Other Demen 2004;19:213-214. 3. Carroll BT, Kennedy JC, Goforth HW. Catatonic signs in medical and psychiatric catatonias. CNS Spectr 2000;5:66-69. 4. Salam S, Kilzieh N. Lorazepam treatment of psychogenic catatonia: an update. J Clin Psychiatry 1988;49 Suppl:16-21. 5. Northoff G. Brain imaging in catatonia: current findings and a pathophysiologic model. CNS Spectr 2000;5:34-36. 6. Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007;19:406-412. 7. Alisky JM. Lorazepam-reversible catatonia in the elderly can mimic dementia, coma, and stroke. Age Ageing 2007;36:229. Disclosure: the authors report no conflicts of interest. All content in Neurological Bulletin, unless otherwise noted, is licensed under a Creative Commons Attribution-Noncommercial-Share Alike License http://creativecommons.org/licenses/by-nc-sa/3.0/ (ISSN 1942-4043) 16